XNASRADX
Market cap32mUSD
Jan 08, Last price
4.03USD
1D
-13.33%
IPO
-77.19%
Name
Radiopharm Theranostics Ltd
Chart & Performance
P/E
—
P/S
47,280.03
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
299k
+2.35%
Net income
-48m
L+38.54%
CFO
-23m
L-0.97%
Earnings
Apr 15, 2025
Profile
Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | |
| Income | ||||
Revenues | 299 2.35% | 292 3,210.60% | 9 | |
Cost of revenue | 54,385 | 40,585 | 19,545 | |
Unusual Expense (Income) | ||||
NOPBT | (54,086) | (40,292) | (19,536) | |
NOPBT Margin | ||||
Operating Taxes | 96 | (5,879) | 44 | |
Tax Rate | ||||
NOPAT | (54,182) | (34,413) | (19,580) | |
Net income | (47,949) 38.54% | (34,611) 14.08% | (30,339) 6,153.01% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 26,578 | 8,363 | 65,169 | |
BB yield | -180.98% | -24.60% | -155.29% | |
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | 27,107 | 16,141 | 12,540 | |
Net debt | (18,575) | (11,739) | (27,019) | |
| Cash flow | ||||
Cash from operating activities | (22,976) | (23,202) | (9,907) | |
CAPEX | (5) | (1,531) | (28,339) | |
Cash from investing activities | (1,531) | (28,370) | ||
Cash from financing activities | 29,877 | 9,218 | 65,110 | |
FCF | (54,175) | (34,480) | (19,654) | |
| Balance | ||||
Cash | 18,575 | 11,699 | 26,979 | |
Long term investments | 40 | 40 | ||
Excess cash | 18,560 | 11,724 | 27,019 | |
Stockholders' equity | 27,353 | 45,579 | 62,963 | |
Invested Capital | 35,900 | 49,996 | 48,484 | |
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 386,460 | 323,817 | 279,770 | |
Price | 0.04 -63.81% | 0.11 -30.00% | 0.15 | |
Market cap | 14,685 -56.81% | 34,001 -18.98% | 41,965 | |
EV | (4,659) | 23,457 | 14,946 | |
EBITDA | (50,959) | (36,996) | (16,554) | |
EV/EBITDA | 0.09 | |||
Interest | 643 | 86 | 9,350 | |
Interest/NOPBT | ||||